周一“星”视角|在高容量中心行食管切除后情况；放化疗联合免疫化疗作为不可切除局部晚期食管鳞癌转化治疗：NEXUS-1 II期试验

文章预览

本期胸小星将为大家带来 在高容量中心行食管切除后情况；放化疗联合免疫化疗作为不可切除局部晚期食管鳞癌转化治疗：NEXUS-1 II期试验 ，一起来看看吧！ 2017·EATTS  01 Travel to High-Volume Centers and Survival After Esophagectomy for Cancer Sara Sakowitz1, Syed Shahyan Bakhtiyar1 2, Saad Mallick1 3, Jane Yanagawa4, Peyman Benharash1 3 1 Cardiovascular Outcomes Research Laboratories (CORELAB), University of California, Los Angeles. 2 Department of Surgery, University of Colorado, Aurora. 3 Center for Advanced Surgical & Interventional Technology, Department of Surgery, University of California, Los Angeles. 4 Division of Thoracic Surgery, Department of Surgery, University of California, Los Angeles. Objective:   Ongoing efforts have encouraged the regionalization of esophageal adenocarcinoma treatment to high-volume centers (HVCs). Yet such centralization has been linked with increased patient travel burden and reduced ………………………………